Clinical efficacy of Moxifloxacin in the treatment of Bacterial Keratitis: A Randomised Clinical Trial

Phase 3

Completed

• Conditions: Bacterial Keratitis; Eye - Diseases / disorders of the eye

• Registration Number: ACTRN12606000406505
• Lead Sponsor: Centre for Eye Research Australia

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2006-09-18
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 229

Inclusion Criteria

Patients at least one year of age, of any race and either sex.•Have a diagnosis of bacterial keratitis based on clinical observation.•Must be able to understand and sign an informed consent form that has been approved by the Human Research and Ethics Committee. If the patient is under 18 years of age, the informed consent must be understood and signed by the patient’s legally authorized representative (parent or guardian).•Must agree to comply with the visit schedule and other requirements of the study. The parent or guardian must agree to ensure compliance of patients less than 18 years of age.•If patients have an infection in both eyes, then only one will be treated with the study medication.

Exclusion Criteria

Known allergy to fluoroquinolones, aminoglycosides, penicillins, cephalosporins or benzalkonium chloride.•Pregnant females.•Patients under 1 year of age.•Suspected fungal, viral (e.g. Herpes simplex) or Acanthomoeba infection based on clinical observation.•Patients to be treated with subconjunctival injection(s) of antibiotic(s).

Study & Design

• Study Type: Interventional
• Study Design: Not specified